# **AU InforMed**

#### Volume 21 Number 4 (Issue 330)

Friday, July 14, 2023

Guest Editors: Maggie Whatley, Pharm.D. Candidate 2024, Jordan Rogers, Pharm.D. Candidate 2024, Noha Ahmed, Pharm.D. Candidate 2024, Wesley Lindsey, Pharm.D.





## Key Inforbits

- What is World Brain Day?
- Alzheimer's Disease
- New Drugs in Alzheimer's Disease
- Mental Health
- New drugs in Alzheimer's and Depression
- Non-pharmacological treatment

## World Brain Day, July 22<sup>nd</sup>

## What is World Brain Day?<sup>1-4</sup>

- World Brain Day was established by the World Federation of Neurology in 2014 in hopes to bring public awareness and promote advocacy related to brain health.
- World Brain Day is held on July 22nd every year.
- The theme for this year's World Brain Day is "Leave No One Behind", a focus on Brain Health and Disability.
- The goal of this day is to spread awareness, help prevent brain disabilities, encourage more access to health care resources for these disabilities, and provide more education and advocate for those living with brain disabilities. Brain disabilities would include disorders like Alzheimer's Disease, dementia, brain cancer, epilepsy and seizure disorders, mental disorders, Parkinson's Disease and movement disorders, along with disabilities caused by strokes or TIAs.



## **Alzheimer's Disease**<sup>5-14</sup>

Alzheimer's Disease is the most common type of dementia that involves the parts of the brain that control language, thought, and memory. An estimated 6.7 million Americans age 65 and older are living with Alzheimer's as of 2023. This disease is progressive and begins with mild memory loss and may lead to the loss of ability to communicate and respond to the environment. The exact cause of this disease is currently unknown but there are different theories on whether or not there is a genetic or environmental connection. The common symptoms could include memory loss, aphasia (unable to speak or understand those that are speaking), apraxia (unable to carry out coordinated movements), agnosia (unable to identify something or someone), disorientation, impaired executive function, depression, psychotic symptoms like hallucinations or delusions, behavioral disturbances, or inability to care for yourself.

As of July 6th, 2023, lecanemab

#### Did you know there is a new drug for Alzheimer's Disease?

- What drug? lecanemab (Leqembi)
- What is their role/why are these different or important?



https://www.eisai.com/news/2022/news202285.ht



(Leqembi) has received full FDA approval for use in those with mild cognitive impairment or in the mild dementia stage of Alzheimer's Disease. Lecanemab works by selectively binding and eliminating amyloid-beta aggregates that are believed to contribute to the neurodegenerative process of Alzheimer's Disease. The drug's manufacturer, Eisai, presented evidence from their phase 3 Clarity AD Trial showing that this medication can slow the mental decline of the patient by 27% in comparison to placebo in an 18-month period. Lecanemab works differently in

comparison to other monoclonal antibodies for Alzheimer's Disease, like aducanumab (Aduhelm). Lecanemab mainly targets A $\beta$  protofibrils, while aducanumab and other monoclonal antibodies favor highly aggregated forms of A $\beta$ . Lecanemab's side effects include infusion reactions, amyloid-related imaging abnormalities (AIRA) including AIRA-H (focusing on hemorrhages) and AIRA-E (focusing on edema/effusions), headaches and risk of falling. The approval of this medication comes with a black box warning for brain bleeding or swelling, and the FDA suggests using this medication with caution with those taking anticoagulants or have risk factors for intracranial hemorrhage. Lecanemab also causes fewer incidences of amyloid-related imaging abnormalities and hemorrhages in comparison to aducanumab. This is likely due to the different mechanisms of action for these drugs.

### Ways to Prevent or Lower Your Risk of Alzheimer's Disease:

Control your blood pressure Eat a healthy, balanced diet Be active (at least 150 minutes/week of moderate-intensity exercise) Avoid excessive drinking Get enough sleep Maintain an active social life (avoiding social isolation) Learning to play a musical instrument Control your blood sugar Maintain a healthy weight Quit smoking Prevent or correct hearing loss Reading Treating your depression Learning a new language

## Mental Health<sup>15-20</sup>



https://scoonews.com/news/importance-of-mental-health-awareness-in-school/?noamp=mobile

#### • New drug options:

- Within the past year, a new combination called Auvelity (dextromethorphan and bupropion) was released. This is the first NMDA receptor antagonist for major depressive disorder. The NMDA antagonism of dextromethorphan helps modulate glutamate neurotransmission by affecting the inhibitory tone on interneurons and having a direct action on the postsynaptic NMDA receptor. The sigma-1 receptor agonism of dextromethorphan may help modulate glutamate and monoamine signaling. Bupropion is used to help extend the plasma concentrations of dextromethorphan. In the GEMINI and ASCEND study, Auvelity twice daily decreased the patients' depression rating scores and had significant symptom improvement by week 6 of use.
- Biogen and Sage are currently pursuing FDA approval for a new drug called zuranolone. It is a new 14-day treatment regimen for major depressive disorder and postpartum depression. Zuranolone is a new neuroactive steroid that acts as a positive allosteric modulator of GABA-A receptors. This drug specifically targets brain connections that regulate mood, arousal, behavior, and cognition.

#### • Non-pharmacological treatment

- Lifestyle factors: exercise, healthy eating, limiting or eliminating smoking and drinking alcohol
- A recent guideline on the acute phase of major depressive disorder discusses different nonpharmacologic therapy options that could be used as second-line therapy or add-on therapy to a patient's regimen. The nonpharmacologic therapy options that are available include psychotherapy, CAM (complementary and alternative medicine), St. John's Wort, and exercise. The different psychotherapy options include cognitive behavioral therapy, which includes cognitive therapy, rational emotive behavioral therapy, problem-solving therapy, integrative therapy, psychodynamic therapies, third-wave cognitive behavioral therapy. behavior therapy, behavior modification, and humanistic therapy.

#### • New crisis hotline

In 2022, a new crisis hotline was created to deliver support to anyone who is experiencing a crisis. Those in crisis can call or text **988** or chat online 24/7 at 988lifeline.org and be connected to a trained specialist who can aid in deescalating situations and provide free, confidential support to people in suicidal crisis or emotional distress.

## **Tips to Develop Good Mental Health**



https://twitter.com/BelievePHQ/status/915305749152137216





## FUN FACT: UP TO TWO THIRDS OF THE TOTAL WEIGHT OF A SHARK'S BRAIN IS DEDICATED TO SMELL. MAKE SURE TO TUNE IN FOR SHARK WEEK WITH JASON MOMOA STARTING ON JULY 23RD ON DISCOVERY!

"It is during our darkest moments that we must focus to see the light"



-Aristotle [384 to 322 BC; Greek philosopher]

## References

- 1. World Brain Day Background [Internet]. World Federation of Neurology. 2023 [cited 2023 Jul 4]. Available from: <u>https://wfneurology.org/world-brain-day-background</u>
- World Brain Day 2023 Homepage [Internet]. World Federation of Neurology. 2023 [cited 2023 Jul 4]. Available from: <u>https://wfneurology.org/world-brain-day-2023</u>
- Types of Brain Disorders [Internet]. Reston, VA: The Society of Nuclear Medicine and Molecular Imaging; 2023. [cited 2023 Jul 4]. [about 1 pg.]. Available from: https://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=1781
- 4. B J. Stock Brain images [Internet]. [cited 2023 Jul 4]. Available from: https://stock.adobe.com/search?k=brain&asset\_id=194438143
- CDC. What is alzheimer's disease? [Internet]. U.S. Department of Health & Human Services. Atlanta (GA): Centers for Disease Control and Prevention; 2020 Oct 26 [cited 2023 Jul 4]. Available from: <u>https://www.cdc.gov/aging/aginginfo/alzheimers.htm#:~:text=Alzheimer's%20disease%20is</u> %20the%20most,thought%2C%20memory%2C%20and%20language.
- Alzheimer's Disease Facts and Figures [Internet]. Chicago, IL. Alzheimer's Association; [cited 2023 Jul 4]. Available from: <u>https://www.alz.org/alzheimers-dementia/facts-figures#:~:text=More%20than%206%20million%20Americans%20of%20all%20ages%20have%20Alzheimer's,older%20(10.7%25)%20has%20Alzheimer's.
  </u>
- 7. Crouse EL, Zimmerman KM, Peron EP, et al. Alzheimer Disease. In: DiPiro JT, Yee GC, Haines ST, Nolin TD, Ellingrod VL, Posey L, editors. DiPiro's Pharmacotherapy: A Pathophysiologic Approach. 12th ed [AU Intranet; Access Pharmacy]. New York: McGraw Hill Medical; 2023 [cited 2023 Jul 4]. Chapter 73. Available from: <u>https://accesspharmacy.mhmedical.com/content.aspx?bookid=3097&sectionid=267240515#1</u> 201552118
- 8. McGinley L. Alzheimer's drug Leqembi back by FDA advisers for full approval. The Washington Post [Internet]. 2023 Jun 9 [cited 2023 Jul 4]. [about 4 pg.]. Available from: https://www.washingtonpost.com/health/2023/06/09/alzheimers-drug-leqembi-fda/
- 9. Verger A, Yakushev I, Albert NL, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? the EANM Neuroimaging Committee perspective. Eur J

Nucl Med Mol Imaging. 2023 May [cited 2023 Jul 11];50(6):1553-1555. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119064/

- Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference [Internet], 2022 Nov 30. Bukyo City, Japan: Eisai Global; 2023. [cited 2023 Jul 7]; [about 12 pg.]. Available from: <u>https://www.eisai.com/news/2022/news202285.html</u>
- 11. FDA. FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval, News Release [Internet], 2023 Jul 6. U.S. Department of Health & Human Services. Silver Spring, MD: Food and Drug Administration; 2023 Jul 6 [cited 2023 Jul 7]; [about 3 pg.]. Available from: <u>https://www.fda.gov/news-events/press-announcements/fda-converts-novelalzheimers-disease-treatment-traditional-approval</u>
- New Federal Decisions Make Alzheimer's Drug Leqembi Widely Accessible [Internet], 2023 Jul 6. New York, NY: The New York Times; 2023. [cited 2023 Jul 7]; [about 4 pg.]. Available from: <u>https://www.nytimes.com/2023/07/06/health/alzheimers-leqembi-medicare.html</u>
- CDC. Reducing Risk of Alzheimer's Disease [Internet], 2022 Sep 13. U.S. Department of Health & Human Services. Atlanta, GA: Centers for Disease Control and Prevention; 2022 Sep 13 [cited 2023 Jul 5]. Available from: <u>https://www.cdc.gov/aging/publications/features/reducing-risk-of-alzheimersdisease/index.htm</u>
- 14. Prevention: Alzheimer's Disease [Internet], 2021 Jul 5. London, UK: National Health Service; 2023 [cited 2023 Jul 5]. Available from: <u>https://www.nhs.uk/conditions/alzheimers-disease/prevention/</u>
- 15. ScooNews T. Importance of Mental Health Awareness in School [Internet]. 2022 Dec 29 [cited 2023 Jul 4]. Available from: <u>https://scoonews.com/news/importance-of-mental-health-awareness-in-school/?noamp=mobile</u>
- 16. CDC. Mental Health Information [Internet]. U.S. Department of Health & Human Services. Atlanta (GA): Centers for Disease Control and Prevention.; 2023 Apr 25 [cited 2023 Jul 4]. Available from: <u>https://www.cdc.gov/mentalhealth/learn/index.htm</u>
- 17. Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets, for oral use [Package Insert] [Internet]. NY: Axsome Therapeutics; 2022 Dec [cited 2023 Jul 4]. Available from: <u>https://www.auvelityhcp.com/efficacy</u>
- 18. Biogen and Sage Therapeutics announce FDA accepts filing of New Drug Application and grants priority review of Zuranolone in the treatment of major depressive disorder and postpartum depression. Press Release. [Internet]. 2023 Feb 6 [cited 2023 Jul 4]. Available from: <u>https://investors.biogen.com/news-release/news-release-details/biogen-and-sagetherapeutics-announce-fda-accepts-filing-new</u>
- Qaseem A, Owens D, Etxeandia-Ikobaltzeta I, et al. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: A living clinical guideline from the American College of Physicians [Internet]. Ann Intern Med. 2023 Feb [cited 2023 Jul 4];176(2):239-252. doi: 10.7326/M22-2056. Epub 2023 Jan 24. Available from: <u>https://pubmed.ncbi.nlm.nih.gov/36689752/</u>
- 20. 988 Suicide & Crisis Lifeline [Internet]. 2022 [cited 2023 Jul 4]. Available from: https://www.samhsa.gov/find-help/988
- 21. 15 tips to develop good mental health [Internet]. BelievePHQ; 2017 Oct 3 [cited 2023 Jul 5]. Available from: <u>https://twitter.com/BelievePHQ/status/915305749152137216</u>
- 22. Shark Senses [Internet]. The Shark Trust, Plymouth, UK. 2020 [cited 2023 Jul 5]. Available from: <u>https://www.sharktrust.org/shark-senses</u>

 An electronic bulletin of drug and health-related news highlights, a service of ... Auburn University, Harrison School of Pharmacy, Drug Information Center
 Phone 334-844-4400
 <u>http://www.auburn.edu/academic/pharmacy/dilrc/overview.html</u> Bernie R. Olin, Pharm.D., Director
 Archived issues are available at: <u>http://www.auburn.edu/academic/pharmacy/dilrc/au-informed.html</u>

Health Professional with a Question? Drugs – Therapeutics – Pharmacy Practice? Please contact us. We can help resolve your issue. Please call **344-844-4400** Monday-Friday 8:00 to 5:00 pm (some holidays excepted) or visit our website, 24/7 at: <u>http://www.auburn.edu/academic/pharmacy/dilrc/overview.html</u>